We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sphere Medical | LSE:SPHR | London | Ordinary Share | GB00B551W951 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.40 | 0.35 | 0.45 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
05/3/2019 06:25 | It has been estimated that up to 230 million anesthetic procedures are performed each year in the world with a death rate in the region of 4% and a significant number of patients developing post-operative complications. Most post-operative complications are related to an imbalance between oxygen delivery and oxygen consumption. LiDCO's technology when used in high-risk patients in both intensive care and surgical settings as part of goal-directed hemodynamic therapy has been repeatedly shown to improve patient outcomes through the optimisation of cardiac output and oxygen delivery to tissues preventing situations of hypoperfusion. Given the compelling results from studies utilising hemodynamic monitoring, it is not surprising that interest in the identification and better treatment and monitoring of high-risk surgery patients continues to grow globally, albeit constrained by healthcare budgets in some territories. Within this large market we are focused on specific segments where there is either the strongest clinical evidence (for example: emergency laparotomy) and/or where the uniqueness of our offering differentiates us from the competition (for example: sepsis). | buywell2 | |
04/3/2019 20:25 | It looks the same to me JL.... | del44 | |
04/3/2019 17:31 | Sphere home page has been expanded somewhat. | johnlewis79 | |
04/3/2019 09:35 | Hi Del....a billion pennies is £10m approx 1/10th of the spend to date. Lets hope its multiples of that if we ever get sold.... | johnlewis79 | |
03/3/2019 20:26 | Sepsis clinical paper by Hata J, Stotts C, Shelsky C, Bayman E, Frazier A, Wang J, Nickel E. Reduced mortality with noninvasive hemodynamic monitoring of shock. J Crit Care. 2011;26(2):224.E1-8. ''Treatment of patients using the LiDCOplus monitor significantly reduced the observed mortality rate to 13% against 32% and 20% in the invasively monitored and 37% in the unmonitored patient groups'' One of the biggest clinical trials ever in the UK is now underway using Hemodynamic Monitoring (fluid optimization) with Lidco involved as they now have 60% of the NHS market share and rising, in this area also , see link FLuid Optimisation in Emergency LAparotomy Trial FLO-ELA is the FLuid Optimisation in Emergency LAparotomy trial. It is a large pragmatic clinical trial which aims to find out whether cardiac-output guided haemodynamic therapy given to patients during and shortly after emergency bowel surgery could save lives, when compared with usual care. The trial is being run in 100 UK hospitals and will study nearly 8000 patients. This project is funded by the National Institute for Health Research Health Technology Assessment programme (project number 15/80/54). IMO Lidco should do well in the above Flo-Ela trial Emergency Laparotomy Emergency abdominal surgery is associated with high mortality rates from 14% to 19% in 3 large retrospective studies in the UK, US and Denmark. This rises to over 24% in patients over 80 years of age. | buywell2 | |
03/3/2019 15:17 | So ....keeping Sphere...cause he knows it will be worth BILLIONS very soon.....>:-) | del44 | |
03/3/2019 08:36 | .....after changes to his portfolio on Friday W said he would look to further reduce exposure to individual unquoted companies. Having listened to feedback from clients he believes that moving exposure to that asset class via a collective fund rather than individual unquoted stocks makes sense. Craig Newman CEO of his firm W invsmnt Mngmt said "Neil is as passionate on the unsuited class as ever" Contacted by 'Money W said he was exchanging £72.9m of holdings in small unlisted companies for shares in his own PCT. The cos sold off were Atom Bank,Carrick Therapeutics, Cell Media,Rate Setter & Spin Memory. | johnlewis79 | |
03/3/2019 08:24 | Cellis94. Also wish you well. Been through it as well | bobbyboy1958 | |
27/2/2019 08:27 | I wish you well.. | johnlewis79 | |
26/2/2019 16:10 | cellis94, hope results are good. MRI is fairly good at picking up any areas of concern in the prostate, so hopefully just watch and wait (been through it recently) | waterloo01 | |
26/2/2019 16:08 | NHS more good service updates , after a second high number in my blood test re my prostrate and a visit to the doctors a appointment was X given within 26 hours at the Urology Deptwhich was exactly 7 days after the doctors visit and today after visiting the Urology Dept at 9 o'clock I was in another hospital having a MRI scan , that's certainly a world class service . Let's hope the results are equally pleasing. | cellis94 | |
26/2/2019 08:23 | The most expensive in patient hospital cost in US hospitals are sepsis patients which averages $18000 per hospital stay. With over 1.5m sepsis hospital stays per year that costs c$27bn per annum. On average 30% of patients diagnosed with sepsis die. Early diagnosis is crucial from a GP (info about your illness)and then a blood test can indicate the possibility of sepsis so treatment can begin. A 2006 study showed that the risk of death from sepsis increases by an average of 7%-8% for every hour that passes before treatment begins. | johnlewis79 | |
24/2/2019 08:56 | I might be talking to the converted , sepsis is a infection caused by bacteria or lack of blood supply causing the immune system to attack your own vital organs, I friend of mine whom I crown green bowls with has developed a condition where her immune system is attacking her body causing at the moment only the lower half of her face to become a bright scarlet red colour , most worrying for her whether she has a yet undiscovered problem I or she or the doctors at this stage don't know | cellis94 | |
22/2/2019 05:54 | Cheers Del...no reply from Sphere. They probably thought my query was silly and not worth bothering with.... | johnlewis79 | |
21/2/2019 21:05 | How do you identify sepsis? Tests to diagnose sepsis. Sepsis is often diagnosed based on simple measurements such as your temperature, heart rate and breathing rate. You may need to give a blood test. Other tests can help determine the type of infection, where it's located and which body functions have been affected. Or to put it another way....if you end up in an ICU with Sepsis....the Proxima would be handy.....as it would quickly show up in your blood analytes.... | del44 | |
21/2/2019 06:08 | I seem to remember an American Co had a similar drop of blood device that subsequently went t's up...wasn't it Miss Holmes who ran the Co? Not sure if it was comparable to the one you mentioned. Pretty sure Sphere would have known/tested this drop of blood device as there are handheld bg devices used today. Perhaps Del will be more in the know? | johnlewis79 | |
21/2/2019 05:59 | I have contacted Sphere re the sepsis device you talked about. Soon as I hear anything I'll let you know. | johnlewis79 | |
20/2/2019 16:20 | A big plus for the NHS , I had my prostrate checked out 3 to 4 years ago , and as I'm now 70 had a NHS m.o.t my result were good apart from my prostrate number , I had another test which was slightly lower , but higher than they would like to see it , so I went to the Doctors , Tuesday morning appointment 9.20 today at 10.30 the hospital called with a appointment for next Tuesday morning at 9.00 now that the service we would all like to see. | cellis94 | |
20/2/2019 16:07 | Did you see the BBC News , Monday or Tuesday morning re sepsis, a University had developed a sensor, on which you place a single drop of blood that can indicate almost immediately wether a patient has sepsis , with adaptions to its range of detections it could easily ,in my opinion , make PROXIMA redundant , I guess you might be able to see a rerun from the BBC website, I'd be interested to hear your views | cellis94 | |
18/2/2019 06:36 | The BG mrkt size dwarfs that of Proton Partners as does the patient nos. Whether one can compare Proton's expected valuation to one for Sphere I doubt however on vol of business alone there seems no comparison. However Sphere has never had a value exceeding £100m. From memory each year over 340m bg tests are performed annually worldwide and c.12m arterial lines are used. Sphere might capture 10% so at c.£200 per disposable the mrkt size would be c.£200m pa. This has likely increased with added analytes (lactate/sepsis) and increased patient groups (neonates/aged). These could raise the nos of P4+(5)to 4-5 units per every 10 ITU beds. Well as we know it was a great story that invstrs became over enthusiastic about... the medicos less it must be said owing to the torturous purchase decisions and changing the "it aint broke so why"practices. How Sphere has overcome these type drawbacks remain to be seen as it's now been c.18 months since delisting. We expect to see some progress on auto and PMA or 510k approval even poss partnership if we ever sell any P. | johnlewis79 | |
17/2/2019 11:52 | I hate to get my hopes up after so many years stranded here, so it's a spin of the coin. Have to say the Proton valuation seems a bit rich given the target patients of c.1500 per year but I'll be missing something I'm sure. I've always said if Sphere cannot demonstrate demand for P why would anyone be interested unless....It's to use the technology outside of patient care and I cannot see that given the size of the BG mrkt? Perhaps W will have a clearer idea of Spheres future come the annual results? Methinks 2019 is the end of the road so it's either the highway or the bye bye way. | johnlewis79 | |
17/2/2019 10:50 | johnlewis79 - Could Proton possiby be a "straw in the wind" indicating some hope still for Sphere? | pugugly | |
17/2/2019 08:47 | Woodford seeks to float Proton Partners in a £320m float on the NEX Exchange based in London. The Co was valued at £165m when it raised £25m last year. A listing would provide W with some welcome liquidity after some disappointments in his life sciences portfolio. Proton is a private company developing beam therapy seen as a safer bet than traditional radiotherapy for some cancers. Recently available on the NHS though treatment is limited to c.1500 patients a year. It's part of our long-term growth strategy and we see NEX as the ideal stepping stone for Proton going into a more structured public market environment. | johnlewis79 | |
08/2/2019 09:54 | No idea wot ur on about DD So will give it a miss...thanx anyways | johnlewis79 | |
08/2/2019 08:16 | What do you mean by posts? you mean discussion threads? If it's threads it's to do with the fact they are promoted by the in site crypto coin 'Plus1'. I have a few plus1, so in theory I could get this thread on the main threads page at the top of the list - not that I want to do that. Threads or posts are voted up by the little grey circle with a 'Plus' in it. If you want a few coins to play with let me know. | dusseldorf |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions